Susmed Inc
TSE:4263
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
414
968
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Susmed Inc
Cost of Revenue
Susmed Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Susmed Inc
TSE:4263
|
Cost of Revenue
-ÂĄ12.3m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
M3 Inc
TSE:2413
|
Cost of Revenue
-ÂĄ145.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-21%
|
|
|
EM Systems Co Ltd
TSE:4820
|
Cost of Revenue
-ÂĄ11.8B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-9%
|
|
|
S
|
Software Service Inc
TSE:3733
|
Cost of Revenue
-ÂĄ28.1B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-10%
|
|
|
Medley Inc
TSE:4480
|
Cost of Revenue
-ÂĄ10.4B
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
|
JMDC Inc
TSE:4483
|
Cost of Revenue
-ÂĄ20.2B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
Susmed Inc
Glance View
SUSMED, Inc. engages in the development of medical equipment and software systems. The company is headquartered in Chuo-Ku, Tokyo-To. The company went IPO on 2021-12-24. The firm operates through two business segments. The DTx Product segment is engaged in the development of application software products for treating diseases such as insomnia, breast cancer, chronic kidney diseases and others. The DTx Platform segment is engaged in the provision of general-purpose clinical trial systems and machine learning automatic analysis systems, as well as the provision of DTx development support services using systems.
See Also
What is Susmed Inc's Cost of Revenue?
Cost of Revenue
-12.3m
JPY
Based on the financial report for Jun 30, 2025, Susmed Inc's Cost of Revenue amounts to -12.3m JPY.
What is Susmed Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-51%
Over the last year, the Cost of Revenue growth was -5%. The average annual Cost of Revenue growth rates for Susmed Inc have been -6% over the past three years , -51% over the past five years .